Therefore, although the “gold standard” for synovial sarcoma is molecular testing, TLE1-targeted therapeutics could be used to selectively treat synovial sarcoma without damaging host tissue and could be a useful immunohistochemical marker in combination with CD37, CK7, EMA, BCL2, and MIC2 [27]. Here, TLE1 is linked to synovial sarcoma.